Elevated Galectin-1 Levels in Sepsis Reflect Danger of Cytokine Storm Development
By LabMedica International staff writers Posted on 11 Jan 2021 |
Image: Molecular model of the galectin-1 protein (Photo courtesy of Wikimedia Commons)
Increased concentration of the beta-galactoside-binding protein “galectin-1” in sera from human sepsis patients has been found to be a novel biomarker for cytokine storms that may occur in cases with runaway sepsis.
Cytokine storms form during sepsis due to the overreaction of the body to an infection. Cells damaged as a result of infection or injury release cytokines and other danger molecules called alarmins that can generate a cytokine storm.
Damage-associated molecular patterns (DAMPs), also known as danger-associated molecular patterns, danger signals, and alarmin, are host biomolecules that can initiate and perpetuate a noninfectious inflammatory response. For example, they are released from damaged or dying cells and activate the innate immune system by interacting with pattern recognition receptors (PRRs). In contrast, pathogen-associated molecular patterns (PAMPs) initiate and perpetuate the infectious pathogen-induced inflammatory response. DAMPs are key determinants that shape the aftermath of inflammatory cell death. However, the identity and function of the individual DAMPs released are poorly defined.
Investigators at the University of Connecticut (Storrs, USA) and their colleagues sought to the determine the identity and function of individual DAMPs released in response to cytosolic lipopolysaccharide (LPS).
Galectin-1 release is a common feature of inflammatory cell death and galectin-1 promotes inflammation and plays a detrimental role in LPS-induced lethality. The investigators found that sepsis patients had higher levels of galectin-1 than those found in non-sepsis critical care patients or in healthy individuals. On the molecular level, galectin-1 inhibition of CD45 (Protein tyrosine phosphatase, receptor type, C) seemed to be the cause of its unfavorable role in promoting cytokine storms.
The galectin-1 study was published in the January 4, 2021, online edition of the journal Nature Immunology.
Related Links:
University of Connecticut
Cytokine storms form during sepsis due to the overreaction of the body to an infection. Cells damaged as a result of infection or injury release cytokines and other danger molecules called alarmins that can generate a cytokine storm.
Damage-associated molecular patterns (DAMPs), also known as danger-associated molecular patterns, danger signals, and alarmin, are host biomolecules that can initiate and perpetuate a noninfectious inflammatory response. For example, they are released from damaged or dying cells and activate the innate immune system by interacting with pattern recognition receptors (PRRs). In contrast, pathogen-associated molecular patterns (PAMPs) initiate and perpetuate the infectious pathogen-induced inflammatory response. DAMPs are key determinants that shape the aftermath of inflammatory cell death. However, the identity and function of the individual DAMPs released are poorly defined.
Investigators at the University of Connecticut (Storrs, USA) and their colleagues sought to the determine the identity and function of individual DAMPs released in response to cytosolic lipopolysaccharide (LPS).
Galectin-1 release is a common feature of inflammatory cell death and galectin-1 promotes inflammation and plays a detrimental role in LPS-induced lethality. The investigators found that sepsis patients had higher levels of galectin-1 than those found in non-sepsis critical care patients or in healthy individuals. On the molecular level, galectin-1 inhibition of CD45 (Protein tyrosine phosphatase, receptor type, C) seemed to be the cause of its unfavorable role in promoting cytokine storms.
The galectin-1 study was published in the January 4, 2021, online edition of the journal Nature Immunology.
Related Links:
University of Connecticut
Latest Molecular Diagnostics News
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection